FLT1 and glioma: Positive immune responses against VEGFR1 and VEGFR2 in PBMCs were induced in 87.5% and 12.5% of patients, respectively, suggesting that the VEGFR1-derived epitope was immunogenic in advanced high grade glioma patients.